Blocking interleukin-1β in acute and chronic autoinflammatory diseases

Journal of Internal Medicine

Volumn 269, Issue 1, 2011, Pages 16-28

  Dinarello, C A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Diabetes; Heart failure; Inflammation

Indexed keywords

ADALIMUMAB; ALLOPURINOL; DEXAMETHASONE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ACUTE DISEASE; AUTOINFLAMMATORY DISEASE; CHRONIC DISEASE; CONFERENCE PAPER; CYTOKINE RELEASE; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME ACTIVITY; GOUT; HEART FAILURE; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOCYTE; MULTIPLE MYELOMA; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OPPORTUNISTIC INFECTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; GOUT; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INTERLEUKIN-1BETA; MULTIPLE MYELOMA;

EID: 78650224244     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02313.x     Document Type: Conference Paper

References (96)

1. Auron PE, Webb AC, Rosenwasser LJ et al. Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci USA 1984; 81: 7907-11.
2. Lomedico PT, Gubler R, Hellmann CP et al. Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature 1984; 312: 458-62.
3. Dinarello CA, Renfer L, Wolff SM. Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci USA 1977; 74: 4624-7.
4. Rosenwasser LJ, Dinarello CA, Rosenthal AS. Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med 1979; 150: 709-14.
5. McAdam KPWJ, Dinarello CA. Induction of Serum Amyloid A Synthesis by Human Leukocytic Pyrogen, in Bacterial Endotoxins and Host Response. Agarwal MK, ed. Amsterdam: Elsevier/North-Holland and Biomedical Press, 1980; 167-78.
6. Dinarello CA. Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 1984; 311: 1413-8.
7. Kawakami M, Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 1981; 154: 631-9.
8. Dayer JM, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163-8.
9. Gay NJ, Keith FJ. Drosophila Toll and IL-1 receptor. Nature 1991; 351: 355-6.
10. Sims JE, March CJ, Cosman D et al. cDNA expression cloning of the IL-1 receptor, a member of the immunoglobulin superfamily. Science 1988; 241: 585-9.
11. Heguy A, Baldari C, Bush K et al. Internalization and nuclear localization of interleukin 1 are not sufficient for function. Cell Growth Differ 1991; 2: 311-5.
12. Heguy A, Baldari CT, Macchia G, Telford JL, Melli M. Amino acids conserved in interleukin-1 receptors (IL-1Rs) and the Drosophila toll protein are essential for IL-1R signal transduction. J Biol Chem 1992; 267: 2605-9.
13. Bresnihan B, Newmark RD, Robbins S, McCabe DP, Genant HK. Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis. Arthritis Rheum 2000; 43(suppl 9): S289.
14. Genant HK, Bresnihan B, Ng E, Robbins S, Newmark RD, McCabe D. Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis. Ann Rheum Dis 2001; 40(suppl 1): 169 (abs).
15. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol 1999; 163: 5049-55.
16. Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002; 41: 972-80.
17. Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford) 2003; 42(Suppl 2): ii22-8.
18. Joosten LA, Smeets RL, Koenders MI et al. Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. Am J Pathol 2004; 165: 959-67.
19. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology 2002; 39: 237-46.
20. Chevalier X, Goupille P, Beaulieu AD et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009; 61: 344-52.
21. Masters SL, Simon A, Aksentijevich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009; 27: 621-68.
22. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-5.
23. McDermott MF, Aksentijevich I, Galon J et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97: 133-44.
24. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607-12.
25. Goldbach-Mansky R, Dailey NJ, Canna SW et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355: 581-92.
26. Hoffman HM, Rosengren S, Boyle DL et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist prevents. Lancet 2004; 364: 1779-85.
27. Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1 receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003; 348: 2583-4.
28. Hoffman HM, Throne ML, Amar NJ et al. Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008; 58: 2443-52.
29. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
30. Gattorno M, Piccini A, Lasiglie D et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 1505-15.
31. Dinarello CA, Ikejima T, Warner SJ et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987; 139: 1902-10.
32. Dinarello CA, Cannon JG, Wolff SM et al. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med 1986; 163: 1433-50.
33. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007; 13: 851-6.
34. Cohen I, Rider P, Carmi Y et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA 2010; 107: 2574-9.
35. Kaplanski G, Farnarier C, Kaplanski S et al. Interleukin-1 induces interleukin-8 from endothelial cells by a juxacrine mechanism. Blood 1994; 84: 4242-8.
36. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity 2004; 20: 319-25.
37. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005; 201: 1479-86.
38. Netea MG, Nold-Petry CA, Nold MF et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 2009; 113: 2324-35.
39. Okamoto M, Liu W, Luo Y et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J Biol Chem 2009; 285: 6477-88.
40. Gattorno M, Tassi S, Carta S et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007; 56: 3138-48.
41. Perregaux DG, McNiff P, Laliberte R, Conklyn M, Gabel CA. ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood. J Immunol 2000; 165: 4615-23.
42. Lachmann HJ, Lowe P, Felix SD et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-36.
43. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1b in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 314-21.
44. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008; 29: 334-50.
45. Mandrup-Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, Nielsen JH. Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia 1986; 29: 63-7.
46. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-60.
47. Boni-Schnetzler M, Boller S, Debray S et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology 2009; 150: 5218-29.
48. Boni-Schnetzler M, Thorne J, Parnaud G et al. Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008; 93: 4065-74.
49. Maedler K, Sergeev P, Ehses JA et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 2004; 101: 8138-43.
50. Maedler K, Storling J, Sturis J et al. Glucose- and interleukin-1beta-induced beta-cell apoptosis requires Ca2+ influx and extracellular signal-regulated kinase (ERK) 1/2 activation and is prevented by a sulfonylurea receptor 1/inwardly rectifying K+ channel 6.2 (SUR/Kir6.2) selective potassium channel opener in human islets. Diabetes 2004; 53: 1706-13.
51. Stienstra R, Joosten LA, Koenen T et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cytokine 2009; 48: 134 (abs).
52. Toda Y, Tsukada J, Misago M, Kominato Y, Auron PE, Tanaka Y. Autocrine induction of the human pro-IL-1beta gene promoter by IL-1beta in monocytes. J Immunol 2002; 168: 1984-91.
53. van Asseldonk EJP, Stienstra R, Koenen TB et al. The effect of the interleukin-1 cytokine family members IL-1F6 and IL-1F8 on adipocyte differentiation. Obesity 2010; 18: 2234-36.
54. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-26.
55. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32: 1663-8.
56. Donath MY, Weder C, Brunner A et al. XOMA 052, a potential disease modifying anti-1L-1beta antibody, shows sustained HbA1c reductions 3 Months after a single injection with no increases in safety parameters in subjects with Type 2 diabetes. Diabetes 2009; 58: A30.
57. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24: 325-31.
58. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
59. Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 1998; 139: 4928-35.
60. Goren I, Muller E, Pfeilschifter J, Frank S. Severely impaired insulin signaling in chronic wounds of diabetic ob/ob mice: a potential role of tumor necrosis factor-alpha. Am J Pathol 2006; 168: 765-77.
61. Li Z, Yang S, Lin H et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
62. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 2006; 166: 902-8.
63. Dominguez H, Storgaard H, Rask-Madsen C et al. Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res 2005; 42: 517-25.
64. Rosenvinge A, Krogh-Madsen R, Baslund B, Pedersen BK. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. Scand J Rheumatol 2007; 36: 91-6.
65. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-5.
66. Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab 2000; 85: 1316-9.
67. Lo J, Bernstein LE, Canavan B et al. Effects of TNF-alpha neutralization on adipocytokines and skeletal muscle adiposity in the metabolic syndrome. Am J Physiol Endocrinol Metab 2007; 293: E102-9.
68. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science 1986; 232: 1545-7.
69. Maedler K, Donath MY. Beta-cells in type 2 diabetes: a loss of function and mass. Horm Res 2004; 62(Suppl 3): 67-73.
70. Abbate A, Van Tassell BW, Seropian IM et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail 2010; 12: 319-22.
71. Abbate A, Kontos MC, Grizzard JD et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction. Am J Cardiol 2010; 105: 1371-7.
72. Abbate A, Salloum FN, Vecile E et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008; 117: 2670-83.
73. Singh D, Huston KK. IL-1 inhibition with anakinra in a patient with refractory gout. J Clin Rheumatol 2009; 15: 366.
74. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9: R28.
75. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6: 30-8.
76. Terkeltaub R, Sundy JS, Schumacher HR et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009; 68: 1613-7.
77. Fiehn C, Zeier M. Successful treatment of chronic tophaceous gout with infliximab (Remicade). Rheumatol Int 2006; 26: 274-6.
78. Chen CJ, Shi Y, Hearn A et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116: 2262-71.
79. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.
80. Joosten LA, Netea MG, Myloni E et al. Fatty acids engagement with TLR2 drive IL-1beta production via inflammasome activation by urate crystals in gouty arthritis. Arthritis Rheum 2010; 62: 3237-48.
81. Giamarellos-Bourboulis EJ, Mouktaroudi M, Bodar E et al. Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1-mediated process. Ann Rheum Dis 2009; 68: 273-8.
82. Schindler R, Clark BD, Dinarello CA. Dissociation between interleukin-1β mRNA and protein synthesis in human peripheral blood mononuclear cells. J Biol Chem 1990; 265: 10232-7.
83. Schindler R, Gelfand JA, Dinarello CA. Recombinant C5a stimulates transcription rather than translation of IL-1 and TNF; cytokine synthesis induced by LPS, IL-1 or PMA. Blood 1990; 76: 1631-8.
84. Kaspar RL, Gehrke L. Peripheral blood mononuclear cells stimulated with C5a or lipopolysaccharide to synthesize equivalent levels of IL-1β mRNA show unequal IL-1β protein accumulation but similar polyribosome profiles. J Immunol 1994; 153: 277-86.
85. Chapman PT, Yarwood H, Harrison AA et al. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1997; 40: 955-65.
86. Kolly L, Karababa M, Joosten LA. Inflammatory role of ASC. 2009.
87. Nguyen MT, Favelyukis S, Nguyen AK et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282: 35279-92.
88. Joosten LA, Netea MG, Fantuzzi G et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 2009; 60: 3651-62.
89. Kyle RA, Remstein ED, Therneau TM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007; 356: 2582-90.
90. Torcia M, Lucibello M, Vannier E et al. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors. Exp Hematol 1996; 24: 868-74.
91. Lust JA, Donovan KA. The role of interleukin-1 beta in the pathogenesis of multiple myeloma. Hematol Oncol Clin North Am 1999; 13: 1117-25.
92. Lust JA, Lacy MQ, Zeldenrust SR et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009; 84: 114-22.
93. Andrei C, Dazzi C, Lotti L, Torrisi MR, Chimini G, Rubartelli A. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles. Mol Biol Cell 1999; 10: 1463-75.
94. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc Natl Acad Sci USA 2004; 101: 9745-50.
95. Tassi S, Carta S, Vene R, Delfino L, Ciriolo MR, Rubartelli A. Pathogen-induced interleukin-1beta processing and secretion is regulated by a biphasic redox response. J Immunol 2009; 183: 1456-62.
96. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 1993; 81: 2492-5.